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Abstract 
 
Bio-guided Natural Product Drug Discovery Platform Focused on All-Carbon 
Spirocenter Containing Molecules  
 
Megan Elizabeth Hotard 
 
Natural products remain a vibrant source of novel compounds that can serve as 
molecular probes or therapeutic agents. Of specific interest among biologically 
active terrestrial natural products are spirocycles, which are characterized by 
either a tertiary or quaternary carbon spirocenter. Intrigued by the potential of 
these natural products as potential wound healing agents, we began a campaign 
to isolate, characterize, and develop methodologies towards such spirocycle 
molecules. Herein, we disclose our findings featuring the natural product 
pteropodine, a pentacyclic oxindole with a spirocenter, as the inspiration to 
develop spirocycle methodologies. We have successfully isolated pteropodine 
from the plant Uncaria tomentosa and utilized this natural product as a potential 
lead. We also developed new methodologies to access these spirocycles after 
hypothesizing that a metal-mediated ene-type reaction could proceed under mild 
reaction conditions and tolerate a broad range of substituents to provide 
functionalized structures. The chemical reactions were carried out under inert 
atmosphere, monitored by thin layer chromatography, and analyzed by Mass 
Spectrometry and Nuclear Magnetic Resonance. The biological properties of 
these compounds in a gap closure migration assay are presented. 
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Bio-guided Natural Product Drug Discovery Platform Focused on All-
Carbon Spirocenter Containing Molecules 
 
Introduction 
 
Natural Products 
 
Natural products offer a broad range of complex structures that have been used 
to inspire a variety of therapeutic agents to treat many illnesses ranging from 
cancer to infectious diseases. We chose to utilize the unique structures of these 
natural products as a source of inspiration for new therapeutic to accelerate the 
wound healing process. Considering that terrestrial natural products have been 
used for centuries to treat human disease, we pursued a bio-guided screening 
approach of natural products in pursuit of new potential therapeutic agents. This 
method of drug discovery has been utilized to contribute to 70% of antitumor 
agents approved by the FDA [1]. In order to carry out a thorough study, we 
focused on plants that are known to have been used by Native Americas for their 
medicinal purposes. We evaluated a focused library of plants from North and 
South America to be screened for activity against childhood malignancies and 
wound healing. As outlined in Table 1, North American plants studied included 
Hydrastis Canadensis, Quercus dumosa, Aristolochia leuconeura, Phacelia 
hastate, Acer rubrum, Oenanthe sarmentosa, and Salvia mellifera. Plants 
evaluated from South America include Terminalia catappa, Uncaria tomentosa, 
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Onoclea sensibilis, Ligusticum cf. grayi, Dioscorea bulbifera, Cuphea 
hyssopifolia, and Solanum sisymbrifolium. These plants were prime candidates 
for our natural product drug discovery platform due to their documented 
therapeutic effects as well as their prevalent use in traditional medicines by 
Native American healers.  
 
 
Table 1: Natural Product Drug Discovery Platform 
 
As illustrated in Figure 1, the bio-guided natural product drug screening platform 
commenced with the extraction of the stems and leaves of raw plant materials. 
The plant materials were minced and extracted with isopropanol under reflux 
conditions for two days as depicted in step 1. The isopropanol solution was 
filtered, and the remaining plant material was re-extracted for an additional two 
days. After decanting the solution from the remaining plant material, the two 
solutions were combined and concentrated in the second step. These crude 
extracts were pre-fractionated using a 20 g SNAP Biotage cartridge. Column 
conditions increased linearly from 0 to 100% ethyl acetate in hexane followed by 
North American Plants  
No. Plant 
1 Hydrastis canadensis 
2 Quercus dumosa 
3 Aristolochia leuconeura 
4 Phacelia hastata 
5 Acer rubrum 
6 Oenanthe sarmentosa 
7 Solanum sisymbrifolium 
South American Plants  
No. Plant 
1 Terminalia catappa 
2 Uncaria tomentosa 
3 Onoclea sensibilis 
4 Ligusticum cf. grayi 
5 Dioscorea bulbifera 
6 Cuphea hyssopifolia 
7 Salvia mellifera 
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0 to 20 % methanol in ethyl acetate. Using this method, six fractions were 
produced for each of the fourteen natural products. Pending the results of 
biological studies, fractions that demonstrated activity were further purified using 
a 10 g SNAP Biotage cartridge, illustrated by step 4. Fractions were submitted 
for biological testing against several different catastrophic childhood 
malignancies including plasmodium falciparum as well as for their potential as 
wound healing therapeutics. Fractions were submitted for testing as 3 mg/mL 
solutions in DMSO for a target concentration of 10 mM (assuming a molecular 
weight of 300 g/mol). DNA stain-based assays were used to evaluate the 
fractions’ potential against parasitic childhood malignancies, specifically malaria. 
To evaluate the potential of the fractions as wound healing therapeutics, 
samples were tested against gap-closure migration assays. Fractions that 
exhibit biological activity will be further evaluated and purified using HPLC [2].  
 
 
Figure 1: Bio-Guided Natural Product Drug Screening Platform 
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Based on preliminary biological results, we chose to evaluate the plant Uncaria 
tomentosa from the South American collection of natural products. This plant 
was of heightened intrigue because of its prevalent use in traditional medicine. 
Uncaria tomentosa is a medicinal plant found in the tropical jungles of Central 
and South America that has been used in folk medicine for its 
immunomodulatory, anti-cancer, and anti-inflammatory properties in addition to 
its ability to treat gastric ulcers, diarrhea, gonorrhea, arthritis and rheumatism, 
acne, diseases of the urinary tract, and a variety of cancers.  Characterized as a 
woody, climbing vine belonging to the Rubiaceae family, Uncaria tomentosa 
contains unique curved hooks that contributed to its common name “uña de 
gato” or “cat’s claw” [3-5]. To evaluate this natural product as well as the others 
listed, we utilized a systematic extraction and pre-fractionation method illustrated 
in Figure 1.   
 
 
Figure 2: Uncaria tomentosa Natural Products Summary 
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Due to their therapeutic potential, the components of Uncaria tomentosa have 
been studied in great detail. A general summary of all of the secondary 
metabolites that have been reported from this plant is given in Figure 2. By 
definition, secondary metabolites serve no primary biochemical role in the plant 
but are produced for economic or defensive purposes. The specific compounds 
isolated from Uncaria tomentosa have been difficult to evaluate in great detail 
due to the fact that different isomers are isolated at different times of the year in 
various ratios depending on different stresses that the plant has experienced, 
particularly droughts. Further inconsistencies also exist based on the origin of 
the plant, thus complicating the execution of comprehensive studies of these 
natural products. 
 
 
Figure 3:  Uncaria Tomentosa Natural Products featuring Spirocylces 
 
The key alkaloids isolated from Uncaria tomentosa are illustrated in Figure 3: 
pteropodine, isopteropodine, and mitraphylline. All of these alkaloids are 
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heteroyohimbine-type pentacyclic oxindoles that contain A, B, C, D, and E rings, 
the basic skeleton of which is boxed in Figure 3. The numbers on this boxed 
structure indicate respective carbon positions according to the general labeling 
method. The structural feature of the most interest to us was the key spirocenter 
joining the B and C rings at carbon 7. Spirocenters are defined as fully 
substituted atoms that join two organic molecules that are known as spirocycles 
and can be either all-carbon quaternary centers or tertiary centers.  Spirocylces 
are present in numerous biologically active natural products, and clinically 
relevant compounds that can serve as molecular probes or therapeutic agents 
[6]. However, stereoselective and asymmetric methodologies to construct all 
carbon-carbon spirocenters remain scarce. Our goal in this project was to isolate 
pteropodine and develop methodologies to synthesize simplified oxindole 
compounds to be evaluated against a gap closure migration assay to develop 
potential therapeutics to treat impaired healing, specifically in diabetic and 
immunocompromised patients. We also aimed to explore the chemical space 
within the other pentacyclic oxindole alkaloids found in Uncaria tomentosa, 
which are known to possess wound healing properties due to the unique 
spirocenter structural feature.  
 
Ene Reaction Approach to All-Carbon Spirocenters 
 
We hypothesized that we could access simplified pteropodine-inspired all-carbon 
and indole spirocycles structures using an ene-type reation. The ene reaction, or 
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Alder-ene reaction, has been described as “one of the most simple and 
potentially versatile reactions in organic chemistry, but remains surprisingly 
underexploited” [7]. A general ene reaction is a thermal reaction between an ene 
and enophile to form a new bond through migration of a new double bond and a 
[1,5]-hydrogen shift as illustrated in Figure 4. An ene is defined as an olefin 
containing an allylic H atom, and an enophile is an electron deficient double or 
triple bond that wants to react with the allylic hydrogen. During this pericyclic 
reaction, the double bond on the ene shifts and new C-H and C-C σ bonds are 
formed between the ene and enophile [8]. The mechanism of this Alder-ene 
reaction is quite similar to the allylic system of the Diels-Alder reaction, but in 
place of the Diels-Alder dienophile is the enophile of the ene reaction. Other 
differences arise in the higher temperature required by the Alder-ene reaction 
due to the higher activation energy and stereo-electronic requirement of breaking 
the allylic C-H bond of the ene.  
 
 
Figure 4: Proposed Ene Reaction Mechanism 
 
In addition to the intermolecular Alder-ene reaction is the intramolecular Conia-
ene reaction, a thermal or Lewis acid catalyzed reaction of an unsaturated 
carbonyl compound to yield a cyclic system. Similar to the Alder-ene reaction, 
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the Conia-ene reaction mechanism involves an enolization followed by a [1,5]-
hydrogen shift. Advances involving the general ene reaction have been made 
my Andrew Kende and Koichi Mikami. Kende contributed to the ene reaction 
through his Pd(II) mediated synthesis of bridged and spirocyclic 
bicycloalkenones (Figure 5: Reaction 1) [9]. This facile synthesis suggested that 
Pd(OAc)2-mediated cyclizations might serve as favored routes to bridged and 
spirocyclic bicycloalkenones even when competing conjugated enone formation 
is structurally possible [10]. While this novel synthesis advanced the capabilities 
of the basic ene reaction, they were not able to identify the full mechanism of 
their novel cyclizations leaving more to be discovered about this reaction. 
Mikami made advances toward the versatile ene reaction by introducing chirality 
to these spirocyclic structures. He developed a highly enantioselective 
intramolecular [4+2] cycloaddition reaction catalyzed by cationic chiral Rh 
complexes bearing not only a chiral phosphine but also a chiral diene (Figure 5: 
Reaction 2) [11]. Despite these advances, the ene reaction still requires 
significant activation for the reaction to take place.  Mikami’s reaction, while an 
advance on the ene reaction functionality, still requires an activated system with 
an allylic nitrogen. Milder conditions are needed to make the ene reaction more 
versatile and functional for synthetic chemists. 
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Figure 5: Advances on the Ene Reaction 
 
Our hypothesized ene-type reaction sequence (Figure 5: Reaction 3) will expand 
the practical capabilities of the well-established ene reaction utilizing an 
unactivated, neutral system. We predict that this ene-type reaction will be 
successfully mediated by a metal catalyst instead of the harsh thermal 
conditions typical of an ene reaction to allow for various functional groups to be 
included. Such conditions will enable the ene reaction to produce compounds 
with a broad chemical space, like our proposed indole system (Figure 5: 
Reaction 4). These conditions have not been previously attempted for an ene-
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type reaction and would be a novel addition to the capabilities of the ene 
reaction and a valuable tool for synthetic chemists. Additionally, the resulting 
spirocycles would allow chemists to synthesize various natural products and 
other complex, biologically active structures. Furthermore, the application of our 
spirocycles for wound healing presents a novel opportunity to explore the link 
between natural products and the wound-healing process.  
 
Therapeutic Focus: Wound Healing 
 
Based on the known healing properties of Uncaria tomentosa due to the unique 
properties of its pentacyclic oxindoles, we hypothesized that similar spirocycles 
will also be able to make advances in the general wound healing process, 
specifically for the patients severely affected by impaired healing. Wound 
healing is a complex process in which the skin or another tissue repairs itself 
after chemical or physical insult.  In normal skin, the epidermis (outermost layer) 
and dermis (inner layer) exist in steady-state equilibrium, forming a protective 
barrier against the external environment. By definition, a wound is a “disruption 
of normal anatomic structure and function” that results from pathologic 
processes beginning internally or externally. The four phases of wound healing 
for healthy individuals are hemostasis, inflammation, proliferation or granulation, 
and remodeling or maturation [12]. In order for effective wound healing, proper 
sequence, specific timing, and appropriate duration must all occur precisely. 
Several systemic factors can affect a person’s ability to heal at a normal rate 
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including age, gender, disease, obesity, nutrition, and immune system conditions 
[13]. Specific diseases prone to delayed wound healing include diabetes, 
keloids, fibrosis, jaundice, and uremia. Immunocompromised patients, like those 
undergoing chemotherapy, radiation treatment, and AIDs patients, as well as 
those taking glucocorticoid steroids and non-steroidal anti-inflammatory 
medications, are also at increased risks for delayed wound healing. Non-healing 
wounds affect 3 to 6 million people in the United States, costing an estimated $3 
billion per year [13]. Therefore, the development of therapeutics that enhance 
would healing could result in decreased hospitalization times as well as earlier 
return of patients to their daily functions. Such a wound healing therapeutic 
could allow for a potential savings of $11 billion in total health care costs. 
 
The wound healing process involves an intricate combination of signals and 
pathways to effectively close a wound. This process is often significantly 
disrupted or delayed in diabetic and immunocompromised patients who are 
commonly faced with impaired or delayed wound healing. Impaired healing is 
caused by pathologic inflammation due to an incomplete or uncoordinated 
healing process that may lead to infection and necrosis.  Such delay in the 
wound healing process is the most common complication of diabetic patients 
due to poor glucose control and can take between 12 and 18 months to go to 
proper completion.  A simple injury in these patients can rapidly become a 
serious infection, and require amputations to stop the infections from spreading 
(this is the leading cause of non-traumatic lower limb amputation in the United 
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States).  Despite the significant need for effective therapeutic agents, very few 
treatments are in the drug development pipeline due to the complexity and poor 
understanding of the etiology of the disease [14]. When damage occurs to the 
epithelial cells the wound healing process initiated. This process includes “rapid 
hemostasis, appropriate inflammation, mesenchymal cell differentiation, 
proliferation and migration to the wound site. Following this is suitable 
angiogenesis, prompt re-epithelialization (or re-growth of skin tissues over the 
wound), proper synthesis, cross-linking, and alignment of collagen to provide 
strength to the healing tissue.” 
 
 
Figure 6: Role of Macrophages in Wound Healing. 
 
Figure 6 depicts the various signals that initiate the wound healing process, 
specifically the role that macrophages play. The first stage in this process is 
inflammation, which causes the recruitment of macrophages to the site of the 
injury. Macrophages (Greek for “big eaters”) are white blood cells that are 
produced by differentiation of monocytes based on the type of stimuli received by 
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the tissue. Specifically, macrophages are involved in maintaining the tissue 
homeostasis of the wound healing process, including tissue surveillance and 
immunosuppression. Their main role is “constantly surveying their immediate 
surroundings for signs of tissue damage or invading organisms.” Macrophages 
function in both the innate and adaptive immunity of the body by engulfing and 
digesting cellular debris and stimulating immune cells [15]. There are three key 
types of macrophages involved in wound healing: cytocidal, inflammatory, and 
repair. The macrophage known as cytocidal, or “killer,” removes bacteria and 
other debris from the site of injury to help prevent infection. Another important 
macrophage, the inflammatory macrophage, is recruited by the presence of 1,3 
β-glucan and is responsible for attracting fibroblasts, which synthesize the 
extracellular matrix and collagen, and endothelial cells that provide an 
anticoagulant barrier between the blood vessel wall and the blood. Once the 
inflammatory macrophage recruits these cells to the site of the wound, it 
encourages them to proliferate by producing platelet derived growth factor 
(PDGF), transforming growth factor β (TGF-β), and basic fibroblast growth factor. 
During this process, the fibroblasts produce hyaluronan, which causes the 
monocytes to differentiate into the final repair macrophages, whose function is to 
remodel the extracellular matrix of the wound [16]. Also shown in Figure 6 is the 
presence of reactive oxygen species (ROS), or “chemically reactive molecules 
formed by the partial reduction of oxygen,” in wound healing as the result of near 
infrared light. In normal wound healing, ROS are activated during the 
inflammation phase as a “natural byproduct of normal oxygen metabolism and 
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play a role in signaling and homeostasis.” However, in a delayed wound healing 
system, ROS can contribute to chronic inflammation and infections. As 
described, there are several ongoing processes in wound healing, making it 
difficult to target a single aspect; therefore, we will not attempt to pinpoint a 
specific molecular target but the entire process. We will take a broader screening 
approach to study how spirocycles might affect this wound healing process. 
 
Objectives 
Previous studies involving the systematic evaluation of Uncaria tomentosa 
extracts as potential wound healing therapeutics have been hindered by the 
significant differences in composition between samples. With our proposed ene-
type reaction, we will be able to synthesize precursors of this biologically active 
complex system not previously accessible. Our synthesis of all-carbon and 
indole spirocycles has the potential to unlock facile synthetic routes to key 
spirocycles like those derived from Uncaria tomentosa as well as a wide variety 
of other natural products.  We hypothesize that a modified ene-type reaction can 
be mediated by a metal complex under mild reaction conditions, thus tolerating a 
broad range of functionalities leading to unrestricted substrates. Our research 
strategy consisted of the following systematic approach:  
 
Objective 1: We conducted a bio-guided screening approach of 14 natural 
products that led to the isolation, structure elucidation, and characterization of the 
pentacyclic oxindole pteropodine from the natural product Uncaria tomentosa. To 
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carry out an efficient drug discovery platform, we then conducted structure-
activity relationship studies by making synthetic derivatives of pteropodine.  
 
Objective 2: We evaluated a synthetic approach to simplified terpene and 
oxindole compounds bearing a spirocenter to mimic the structure of the 
biologically active pteropodine. We hypothesized that an ene-type reaction would 
mediate this formation and evaluated a series of transition metal complexes to 
understand how they mediate a potential carbocyclic formation for a terpene 
scaffold. Figure 7 illustrates the general goal of this aim to form a simple, un-
functionalized all-carbon spirocycle. We hypothesized that various transition 
metals and ligands would be able to mediate an ene-type reaction to form a 
variety of intermediates to yield 5, 6, and 7 member rings under mild conditions 
without the need for harsh conditions and/or activating functional groups. 
Transition metals studied include platinum, palladium, indium, and silver alone or 
in combination.  
 
 
Figure 7: Proposed All-Carbon Spirocyclization Reaction (Model A) 
 
To broaden the range of natural products accessible by the ene reaction we 
evaluated the formation of spirocenters on indole scaffolds to obtain the core of 
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oxindoles.  Figure 8 highlights the proposed scheme for synthesizing indole 
spirocycles utilizing proven reactivity from the all-carbon spirocycles to gain 
access to structures similar to the heteroyohimbine-type pentacyclic oxindoles 
illustrated in Figure 3.  With this advance, we will gain access to a broad range of 
natural products bearing key spirocenters through a relatively short synthesis.  
 
 
Figure 8: Proposed Indole Spirocyclization Reactions (Model B) 
 
This approach included screening for metal catalysis, solvents, and ligands, 
allowing us to test for general activity, diastereoselectivity, and enantioselectivity 
respectively. Once we have achieved reactivity with a metal catalyst, we will 
evaluate a variety of solvents to optimize the reaction conditions. In addition, a 
library of ligands was evaluated to further optimize the reaction and gain access 
to a variety of other natural product-like structures. 
 
Objective 3: The biological properties of the isolated natural products (objective 
1) and simplified synthetic compounds featuring spirocenters (objective 2) will be 
tested using a scratch-wound healing, or cicatrisation, assay to identify potential 
therapeutic agents.  Commercially available compounds with known wound 
healing properties will be used as controls.  
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Discussion and Results 
Extraction, Isolation, and Structure Elucidation of Pteropodine 
To begin evaluating pteropodine for its potential therapeutic effects, we extracted 
the Uncaria tomentosa plant material in 200 mL of isopropanol under reflux 
conditions. The extraction produced 10 g of extracts that were collected and 
stored under refrigeration conditions. The extracts were pre-fractionated by hand 
using a silica column with a solvent gradient ranging from 0 to 100% ethyl 
acetate in hexane followed by 0 to 20% methanol in dichloromethane. Seven 
fractions were collected based on solvent gradients and further purified 
individually on the Biotage Isolera 4 utilizing SNAP® 10 g cartridges. Each of the 
seven fractions produced a unique number of compounds whose structures were 
evaluated using 1 and 2 D NMR spectroscopy. These compounds of interest 
were evaluated for their biological activity as potential wound healing 
therapeutics on gap closure migration assays. The extraction process is 
summarized in Figure 1.  
Figure 9 shows the compounds we isolated from the July and September 
collections of Uncaria tomentosa flowers. Pteropodine was not isolated is 
significant amounts from the July collection, and 200 mg were isolated from the 
September collection. Figure 9 illustrates the amounts of pteropodine isolated in 
comparison to other pentacyclic oxindoles present in the flower: isopteropodine, 
pteropodine, alkaloid A, and maruquine.  
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Figure 9: Isolated Ratio of Compounds from Uncaria tomentosa 
 
 
The structure of pteropodine isolated from the fractionation of Uncaria tomentosa 
extracts was confirmed using a COSY experiment seen in Figure 10.  
 
 
Figure 10: 2D characterization of pteropodine using COSY 
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Future Directions: Structure-Activity Relationship Evaluation of 
Pteropodine 
The isolation and structure elucidation of pteropodine from the Uncaria 
tomentosa extracts will allow for future structure activity relationship (SAR) 
studies to better understand its functionality.  This polycyclic natural product 
possesses five rings, and two of these rings can be further manipulated through 
synthesis.  The indole can be alkylated with various groups to probe steric 
factors, whereas the E ring with its unique α,β-unsaturated system can potentially 
undergo cycloaddition reactions, halogenations, reductions, and epoxidations.  At 
least, four synthetic analogues can be synthesized on the highlighted sites 
shown in scheme 1.  The analogues will provide the rationale behind the activity 
of the natural product as a wound healing agent.  
 
 
Scheme 1: Structure-Activity Relationship Evaluation of Pteropodine 
 
Ene Reaction Model Study A: All-Carbon Spirocyclic Compounds 
We began our ene reaction studies by synthesizing an all-carbon spirocycle. 
After exploring the initial reactivity potential of the Pd (II) mediated reaction, we 
expanded on this information and optimized the solvent system as well as other 
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catalysts. Once the conditions were sufficiently optimized, we utilized this known 
reactivity to form spirocycles from an indole core. After we have achieved 
promising synthetic routes, we tested the all-carbon and indole spirocylces for 
their biological activity in assisting the wound healing process via gap closure 
migration assays. 
 
 
Scheme 2: Synthesis of Key Intermediate 9 and Promising Lead Reaction 
Conditions for All-Carbon Spirocylces 
 
Scheme 2 illustrates the synthesis of key precursor 9, which will allow us to test 
our hypothesis for the formation of all-carbon spirocycle 10. The synthesis of 
precursor 9 began with the formation of the side-chain 6. This was achieved 
from compound 5 by first protecting the alkyne with tetramethylsilane (TMS) 
followed by the iodinization of the hydroxyl group. Side chain 6 was coupled with 
the core 7 via lithium diisopropylamide (LDA), a strong bulky base, and the polar 
aprotic solvent hexamethylphosphoramide (HMPA) to increase selectivity and 
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produce the protected compound 8. The TMS protecting group was cleaved by 
tetrabutlyammonium fluoride (TBAF) to yield precursor 9, allowing us to begin 
screening cyclization conditions for the all-carbon system. Experimental details 
and characterization via NMR studies is included in the supporting information. 
 
After the core was successfully synthesized, we began our studies by evaluating 
the ability of various transition metals to mediate the formation of an all-carbon 
spirocycle. Metal catalysts including platinum, palladium, indium, and silver were 
evaluated. We explored a variety of solvents and catalysts to obtain optimized 
reactivity to form these spirocenters. Scheme 2 illustrates the results of our 
optimized conditions for the synthesis of these all-carbon spirocycles via an 
intramolecular ene-type reaction. Spirocycle 10 was formed utilizing key 
intermediate 9 and silver trifluoromethanesulfonate (AgOtf) as a catalyst in 
dichloroethane (DCE).  The reaction proceeded at a mild temperature (50oC) but 
only in poor yields of 10%. However, the ability of this ene-type reaction to 
successfully proceed is very promising for further screening of conditions as well 
as for the formation of an indole system.   
 
Ene Reaction Model Study B: Indole Spirocyclic Compounds 
With the success of forming the all-carbon spirocycles 10 and 11 from model 
studies A, we began synthesizing the core for the indole system. Scheme 3 
illustrates the synthetic route used to afford the key intermediate 18 for the 
indole spirocycles. This synthesis commenced with the esterification of 
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commercially available butyric acid 14 via catalytic amounts of trimethylsilyl 
chloride (TMSCl) producing compound 15 in 98% yield. The protection of the 
nitrogen was a crucial step.  
 
 
Scheme 3: Synthesis of Precursor 18 
 
 
Due to the unique chemical properties of indoles and their basicity, protecting 
compound 15 presented a range of potential complications [12]. If left 
unprotected, the nitrogen could coordinate with the metal catalyst, potentially 
inhibiting the reaction since we are only dealing with catalytic amounts of the 
metal. It is crucial that we chose an appropriate protecting group because the 
protecting group itself has the potential to interfere in the reaction mechanism. 
The protecting group could coordinate with the catalytic metal, which would 
block overall reactivity. Furthermore, the protecting group could cause steric 
hindrance and aromaticity effects, thus blocking activity of the cyclization. For 
these reasons we prepared both the carbamate protected compound 16 with 
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Boc (tert-butyloxycarbonyl) and the sulfonamide protected compound 16a. Due 
to its “umbrella” like structure, the carbamate has the potential to inhibit the 
reaction by causing steric hindrance for the cyclization. If this is the case, the 
sulfonamide’s flat structure and decreased electron withdrawing capabilities 
should provide a viable core for cyclization. This alternative core utilizes the 
protecting group N-(2-pyridyl) sulfonyl chloride [11]. This protecting group was 
boasted to be easily installed and capable of exerting complete regiocontrol over 
the Pd(II) catalyzed C-H bond. If the Boc-protected compound 18 presents 
difficulties in the formation of a spirocycle, we have compound 16a to go back to 
and synthesize an alternate core for this indole system. The synthetic route for 
the formation of compound 16a is illustrated in Scheme 3. We synthesized 
protecting group 20 from 2-mercaptopyridine, 19, using sodium hypochlorite and 
concentrated sulfuric acid. This protecting group 20 was added to methyl ester 
15 via KHMDS (potassium bis(trimethylsilyl)amide) producing our back-up 
intermediate 16a. The percent yield for this protection was not ideal, so further 
evaluation is needed to optimize this reaction.  
 
The Boc protected methyl ester 16 underwent a DIBAL-H (diisobutylaluminum 
hydride) reduction at -78°C, yielding the primary alcohol 78% yield with 22% 
recovered starting material, 16. The primary alcohol underwent iodination 
producing compound 17 in 90% yield, which produced the Boc-protected key 
intermediate alkyne 18 via neat lithium acetylide. All reactions were carried out 
on a multi-gram scale, under inert atmosphere, and monitored by thin layer 
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chromatography and mass spectroscopy. All final compounds were purified and 
characterized using nuclear magnetic resonance. These spectra are included in 
the supporting information.  
 
Once we established successful reactivity of the ene reaction from intermediate 
18 to the indole spirocycle 21 using a metal catalyst (Table 2), we screened 
solvents and ligands to create the most effective synthesis to gain access to a 
broad range of natural-product-like spirocycles with known wound healing 
properties. A brief summary of catalyst screening conditions is given in Table 2. 
Catalysts screened include silver triflate (AgOTf), indium triflate (InOTf), 
scandium triflate (ScOTf), tetrakis(acetonitrile) palladium(II) tetrafluoroborate 
([Pd(MeCN4)](BF4)2), magnesium perchlorate (Mg(ClO4)2), zinc chloride (ZnCl2), 
and a combination of silver and indium triflate. The most promising metal 
catalyst proved to be the combination of silver and indium triflate. Unfortunately, 
good yielding reaction conditions have yet to be identified. The reaction 
proceeds under Lewis acid activation namely, Indium in combination with silver 
triflate as illustrated in Table 2. However, the yields are rather low, and the 
reaction does not proceed to completion. In addition, the retention time of the 
product and starting material does not differ complicating the monitoring of the 
reaction by TLC. Mass spectroscopy is also ambiguous since both starting 
material and parent compound share the same chemical mass. NMR is the only 
experimental approach to follow the reaction and it still needs careful evaluation 
since the metals cause small shifting in the magnetic field, the reaction mixture 
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needs to be purified via column chromatography and high performance liquid 
chromatography (HPLC) in order to properly isolate and identify the product.  
 
 
Table 2: Results of Screening Conditions for Model B Compounds 
 
 
Biological Studies via Cicatrisation Assays 
In order to test the biological activity of the generated molecules, we utilized an 
established gap closure migration assay to determine the compounds’ ability to 
promote cicatrisation, or wound healing. The general principle behind this in vivo 
study is to create a wound or gap in the cells and observe how the cells migrate 
to fill the gap. Figure 11 illustrates the general procedure for the gap-closure 
migration assay. Steps followed include: developing a confluent cell monolayer, 
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creating a “wound” by scratching the cells with a sterile pipette tip, and observing 
how the cells migrate to fill the wound over time. We used commercially 
available natural products with known wound healing properties to provide a 
basis for comparison with our compounds. The preliminary cell line to be studied 
is the MDA-MB231 aggressive breast cancer cell line.  This cell line exhibits the 
most migratory behavior that we have observed, and testing our compounds 
against such a well-documented and rapidly migratory cell line enabled us to 
optimize the assay to be able to test against additional cell lines including MCL7, 
macrophage 677.1, and STO, as they are acceptable model systems for wound 
healing. In order to conduct these assays, we will place a wound healing insert 
in a cell suspension and allow the cells to form a confluent monolayer around 
the insert. Using this insert allows us to create a consistently defined 0.9mm 
wound gap, reducing inter-sample variation common among other methods. 
When the insert is removed, a wound gap is created, and cells can then be 
monitored for proliferation or migration across the wound field. Cell migration 
can be monitored by imaging samples at fixed time points or by time-lapse 
microscopy [17]. 
 
Figure 11: Gap-Closure Migration Assay 
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Cells will continue to migrate across the wound until the wound field is 
completely closed. The rate of wound closure between control and treated cells 
will allow us to determine the efficacy and potential therapeutic relevance of the 
generated compounds [18]. An increased “healing” in reference to control or 
untreated cells is anticipated due to the known wound healing properties of the 
similar spirocycles found in Uncaria tomentosa. Such an increase will indicate 
that that our compounds can assist in the wound healing process, potentially for 
the diabetic and immunocompromised patients previously described. 
Tables 3 and 4 outline the compounds that were tested against the MDA-MB-
231 gap-closure migration assay.  Table 3 lists the compounds from the Uncaria 
tomentosa extraction, the all-carbon spirocycle synthesis, and intermediates in 
the indole synthesis.  
 
Table 3: List of Compounds Tested via Migration Assay 
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Compound 1 was isolated from the fourth fraction of Uncaria tomentosa extracts 
and structure elucidation proved the compound to be pteropodine. Similarly, 
compound 1a was isolated from the first fraction of Uncaria tomentosa extracts 
and its structure was elucidated via 1H, 13C, and 2D NMR studies. All carbon 
spirocycles 10 and 22 were tested for their potential as wound healing agents, 
as well as key intermediates 14 and 18 from the indole Model B system. 
Compound 22 was previously synthesized in lab via the same reaction 
conditions as compound 10 and was included in our wound healing study as a 
reference of a functionalized all-carbon spirocycle. There was not enough 
material generated of the cyclized indole compound 21 to submit for biological 
testing. Table 4 characterizes the controls that were used in the migration assay. 
The natural products Rhodiola crenulata (R. crenulata) and circumin have 
documented wound healing inhibition properties; therefore, we used these two 
compounds for negative controls for our studies. Additionally, all compounds 
submitted for biological testing were in a 50 µM solutions of DMSO, so a sample 
of 0.05% DMSO was used to simulate a positive control, or untreated cells. The 
positive controls were made in solutions of EtOH, thus the 0.1 % EtOH treated 
cells indicate the untreated cells corresponding to these controls.  
Controls Reference 
R. Crenulata Negative Control 
Circumin Negative Control 
0.1% EtOH Vehicle 
0.05% DMSO  Vehicle 
 
Table 4: List of Controls for Migration Assay 
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Figure 12 summarizes preliminary biological results of select compounds tested 
against a gap-closure migration, or cicatrisation, assay as line graphs 
quantifying the effect of the compounds on cell migration. Plotted along the x-
axis is the time progression of the assay in hours. The y-axis shows the relative 
wound density as a percentage of the scratch that has been closed. The 
confluence, or relative area covered by the cells, of the scratch-wound was 
observed over a period of 48 hours.   
 
 
Figure 12: Migration Assay Results 
 
 
As shown in Figure 12, compounds 1 and 1a exhibited accelerated wound 
healing in comparison to the DMSO control. Treatment with all-carbon spirocycle 
10 exhibited wound healing at a rate similar to the circumin control, and 
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spirocycle 22 initially exhibited accelerated wound healing but that rate leveled 
off in a similar manner to the DMSO control after 42 hours. Indole compounds 
14 and 18 inhibited cell migration comparable to the R. crenulata control. Such 
inhibition offers the opportunity to use these compounds as anti-metastases 
therapeutic agents. These preliminary results indicate compounds 1 and 1a 
have potential as wound healing therapeutics. Additional studies are needed to 
confirm these results as well as better quantify the effects of the all-carbon and 
indole compounds.  
The migration of the cells was recorded as pictures via the Essen Bioscience 
IncuCyte. These still images were taken every hour up to 48 hours post-scratch 
and qualitatively depict how the cells treated with compounds 1, 1a, 10, 22, and 
14 migrated across the scratch in comparison to the DMSO control. Due to the 
presence of technical artifacts, these results are indicative of the compounds’ 
preliminary potentials as therapeutic agents, but are not conclusive.  
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Conclusions 
Objective 1: We were able to efficiently process fourteen natural products 
(Hydrastis Canadensis, Quercus dumosa, Aristolochia leuconeura, Phacelia 
hastate, Acer rubrum, Oenanthe sarmentosa, Salvia mellifera. Terminalia 
catappa, Uncaria tomentosa, Onoclea sensibilis, Ligusticum cf. grayi, Dioscorea 
evbulbifera, Cuphea hyssopifolia, and Solanum sisymbrifolium) through a bio-
guided drug discovery process.  This led to the subsequent extraction, isolation, 
and structure elucidation of 200 mg of pteropodine, the structural inspiration for 
our ene-reaction studies.   
Objective 2:  An ene-type reaction scheme was evaluated against all-carbon and 
indole systems. Intermediates 9 and 18 were synthesized in excellent yields to 
allow for the evaluation of cyclization conditions includeding metal catalysis, 
solvents, and ligands to test for general activity, diastereoselectivity, and 
enantioselectivity. All-carbon spirocyclizaiton conditions were realized in 
compound 10 in 10% yield allowing for the continuation and further evaluation of 
reaction conditions. Additionally, conditions were discovered to achieve 
cyclization of indole 18 to form compound 21 in 20% yield. These results indicate 
promise for further functionalization and utilization of an ene-type reaction to 
achieve a wide range of natural products whose structures feature a common 
spirocenter.   
Objective 3: Preliminary biological results indicate that compounds 1 and 1a 
isolated from Uncaria tomentosa exhibit increased migration of cells across a 
scratch-wound indicating their potential as wound healing therapeutics.  
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Supporting Information 
Synthetic procedures and compound characterization 
Reagents of the highest available quality were purchased and used without 
further puriﬁcation unless otherwise stated.  Reactions were monitored by thin-
layer chromatography (TLC) carried out on 0.25 mmol E. Merck silica gel plates 
(60F-254) using UV light for visualization and an ethanolic solution of 
anisaldehyde and heat as developing agents.  Reactions were also monitored by 
using Agilent 1100 series LCMS and a low-resonance electrospray model (ESI) 
with UV detection at 25nm.  Title compounds were purified by flash column 
chromatography using E. Merck silica gel (60, particle size 0.040–0.063 mmol) or 
Biotage Isolera Four with normal-phase silica gel.  1H and 13C NMR spectra were 
recorded on a Bruker (AV-400 or DRX-500 MHz) NMR spectrometer instruments 
calibrated with residual undeuterated solvent (CDCl3: δH =7.26 ppm, δC 
=77.16ppm ; acetone-d6: δH =2.05 ppm , δC =29.84ppm; CD3CN: δH=1.94ppm, δC 
=1.32ppm; CD3OD: δH =3.31ppm, δC =49.00 ppm;  DMSO-d6: δH=2.50ppm, δC 
=39.5ppm; D2O: δH=4.79 ppm) as an internal reference.  The following 
abbreviations were used to designate the multiplicities: s=singlet, d=doublet, 
dd=double of doublets, t=triplet, q=quartet, m=multiplet.  Purity of final 
compounds was >95% based on analytical HPLC and NMR analysis. Yields refer 
to chromatographically and spectroscopically (1H NMR) homogeneous materials.  
Extraction and Isolation of Pteropodine from Uncaria tomentosa 
Uncaria tomentosa plant material was extracted with a Soxhlet apparatus in 200 
mL of isopropanol under reflux conditions for two days.  The isopropanol solution 
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was filtered, and the remaining plant material was re-extracted for an additional 
two days. After decanting the solution from the remaining plant material, the two 
solutions were combined and concentrated. The extraction produced 10 g of 
extracts that were collected and stored under refrigeration conditions. The 
extracts were pre-fractionated by hand using a silica column with a solvent 
gradient ranging from 0 to 100% ethyl acetate in hexane followed by 0 to 20% 
methanol in dichloromethane. Seven fractions were collected based on solvent 
gradients and further purified individually on the Biotage Isolera 4 utilizing SNAP 
10 g cartridges. Each of the seven fractions produced a unique number of 
compounds whose structures were evaluated using 1 and 2 D NMR 
spectroscopy. 
Pteropodine (1)  
Yellow solid; 1H NMR (400 MHz, Chloroform-d) δ 7.55 (s, 
1H), 7.41 (d, J = 2.3 Hz, 1H), 7.21 – 7.15 (m, 1H), 7.02 
(ddd, J = 9.8, 7.1, 2.3 Hz, 1H), 6.84 (dd, J = 7.7, 2.4 Hz, 1H), 4.34 (dd, J = 10.5, 
5.9 Hz, 1H), 3.31 – 3.19 (m, 2H), 2.55 – 2.29 (m, 6H), 2.12 – 1.91 (m, 3H), 1.64 – 
1.53 (m, 6H), 1.29 – 1.22 (m, 6H), 0.93 – 0.82 (m, 3H).13C NMR (126 MHz, 
CDCl3) δ 179.64, 166.60, 153.97, 138.89, 132.70, 126.67, 123.65, 121.59, 
108.81, 108.34, 76.24, 76.19, 75.99, 75.74, 71.13, 70.34, 55.77, 53.14, 52.50, 
49.97, 36.86, 33.83, 29.45, 29.16, 28.25, 17.63, 0.00, -1.02. 
Isolated Compound (1a)  
White solid; 1H NMR (400 MHz, Chloroform-d) δ 5.11 (dp, J = 13.4, 6.7, 6.2 Hz, 
1H), 4.17 – 3.97 (m, 0H), 2.02 (ddp, J = 31.5, 12.7, 6.7, 5.9 Hz, 4H), 1.63 (dd, J = 
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31.7, 5.1 Hz, 4H), 1.28 – 1.16 (m, 2H), 0.97 (d, J = 6.5 Hz, 0H), 0.86 (qd, J = 7.0, 
2.3 Hz, 1H).13C NMR (101 MHz, CDCl3) δ 135.10, 134.89, 131.24, 124.41, 
124.30, 124.27, 77.33, 77.01, 76.69, 39.76, 39.74, 31.60, 28.28, 26.78, 26.67, 
25.70, 25.37, 22.66, 17.68, 16.04, 16.00, 14.12. 
Synthesis of All-Carbon Compounds 
Compound 6 
Compound 6 was achieved from the commercially available 
compound 5 (but-3-yn-1-ol). First, the alkyne of compound 5 was TMS protected 
using butyllithium (BuLi) and trimethylsilane chloride (TMSCl). This protected 
compound underwent iodination of the hydroxyl group using triphenylphosphine 
(PPh3), iodine (I2), and imidazole for an overall yield of 82% for both steps. 
1H 
NMR (400 MHz, Chloroform-d) δ 3.22 (t, J = 7.5 Hz, 1H), 2.79 (t, J = 7.5 Hz, 1H), 
0.16 (s, 4H). 
Compound 8 
The side chain (compound 6) was coupled with the 
commercially available core ethyl-2-(cyclohex-1-en-1-yl) 
acetate (compound 7) using lithium diisopropylamide (LDA) as a strong base and 
hexamethylphosporamide (HMPA) as a polar aprotic solvent to produce 
compound 8 in 72% yield. 1H NMR (400 MHz, Chloroform-d) δ 5.61 (s, 1H), 3.68 
(t, J = 0.9 Hz, 16H), 3.09 (s, 2H), 2.95 (s, 3H), 2.23 – 2.14 (m, 5H), 2.06 – 1.83 
(m, 16H), 1.67 – 1.46 (m, 27H), 0.97 (dd, J = 6.5, 0.7 Hz, 2H), 0.15 (d, J = 0.7 
Hz, 33H). 
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Compound 9 
The TMS protecting group from compound 8 was cleaved by 
tetrabutlyammonium fluoride (TBAF) to yield compound 9 in 99% yield. 1H NMR 
(400 MHz, Chloroform-d) δ 5.63 (ddd, J = 2.5, 1.8, 1.0 Hz, 1H), 5.58 – 5.53 (m, 
0H), 3.68 (s, 6H), 3.12 (s, 1H), 2.95 (dd, J = 1.5, 0.8 Hz, 1H), 2.20 – 2.13 (m, 
2H), 2.07 – 1.89 (m, 9H), 1.84 – 1.73 (m, 1H), 1.68 – 1.50 (m, 8H), 0.97 (d, J = 
6.6 Hz, 1H). 
 
Compounds 10 and 11 
Compounds 10 and 11 were formed by the intramolecular cyclization of 
compound 9 via catalysis by AgOTf in DCE. Compound 10 as formed in 10% 
yields, and compound 11 was formed in 23% yield.  
Compound 10 
1H NMR (400 MHz, Chloroform-d) δ 5.59 (s, 4H), 5.07 (d, J = 1.3 Hz, 
1H), 4.93 (s, 1H). 
 
Compound 11 
1H NMR (400 MHz, Chloroform-d) δ 5.85 – 5.78 (m, 1H), 5.55 – 5.49 
(m, 1H), 5.41 (dp, J = 3.1, 1.6 Hz, 1H), 4.39 (dd, J = 9.7, 6.5 Hz, 0H), 
4.19 (dd, J = 8.1, 5.5 Hz, 1H), 3.80 – 3.58 (m, 1H), 2.88 (dd, J = 6.7, 1.1 Hz, 1H), 
2.70 – 2.59 (m, 2H), 2.59 – 2.51 (m, 0H), 2.32 (tt, J = 6.3, 4.3 Hz, 0H), 2.19 – 
2.07 (m, 1H), 2.05 – 1.92 (m, 3H), 1.81 – 1.62 (m, 6H), 1.63 – 1.51 (m, 4H), 1.51 
– 1.45 (m, 1H), 1.42 (dd, J = 9.4, 2.8 Hz, 1H), 1.40 (s, 0H). 13C NMR (101 MHz, 
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CDCl3) δ 178.47, 130.84, 128.78, 82.22, 42.44, 41.61, 32.53, 28.26, 22.06, 
21.54, 20.97, 18.25. 
 
 
Synthesis of Indole Compounds 
Compound 15 
Commercially available butyric acid (5.0 g, 24.6 mmol) was 
combined with excess methanol (50 mL) at 50oC. A catalytic 
amount of TMSCl was added dropwise to the reaction mixture (0.63 mL, 4.92 
mmol) and the reaction was monitored by TLC and allowed to proceed overnight. 
The reaction was quenched at room temperature with 0.5 mL of Et3N (triethyl 
amine), the solvent was evaporated, and the compound was filtered with 
activated carbon.  
 
Compound 16 
Compound 16 (3 g, 13.8 mmol) was dissolved in a 30 mL 1:1 
solution of TEA and DCM at 0oC. To this solution, (BOC)2O 
(6 g, 27.6 mmol) and a catalytic amount of DMAP (50 mg) 
were added. After 1 hour, the reaction was allowed to reach room temperature. 
Reaction progress was monitored by TLC and went to completion after 4 hours. 
1H NMR (400 MHz, CDCl3) δ 8.15 – 8.07 (d, J = 8.0 Hz, 1H), 7.55 – 7.50 (ddd, J 
= 7.6, 2.4, 1.3 Hz, 1H), 7.39 – 7.35 (s, 1H), 7.33 – 7.27 (m, 1H), 7.25 – 7.19 (m, 
1H), 2.78 – 2.69 (m, 2H), 2.45 – 2.36 (td, J = 7.3, 2.1 Hz, 2H), 2.07 – 2.01 (m, 
2H), 1.71 – 1.62 (d, J = 2.1 Hz, 8H), 1.59 – 1.53 (d, J = 2.7 Hz, 1H). 13C NMR 
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(101 MHz, CDCl3) δ 173.74, 149.70, 135.55, 130.51, 124.26, 122.52, 122.31, 
120.05, 118.93, 115.21, 83.24, 77.48, 77.16, 76.84, 51.42, 33.46, 28.15, 24.41, 
24.21. 
Compound 16a  
Compound 15 (100 mg, 0.46 mmol) was dissolved in 2 mL of 
anhydrous THF.  KHMS (3.68 mL, 1.84 mmol) was added to 
this solution at 0oC and allowed to stir for 30 minutes. To this 
solution, compound 20 (106 mg, 0.60 mmol) was added, and the reaction mixture 
was brought to room temperature.  The reaction was monitored by TLC and 
allowed to stir overnight. The reaction mixture was purified using a SNAP 10 g 
Biotage column.  1H NMR (400 MHz, Chloroform-d) δ 8.59 (s, 1H), 8.01 (s, 1H), 
7.91 (d, J = 1.9 Hz, 1H), 7.58 (t, J = 6.9 Hz, 2H), 7.51 – 7.40 (m, 3H), 7.19 (q, J = 
7.0 Hz, 3H), 7.07 (dt, J = 15.6, 7.4 Hz, 3H), 6.84 (q, J = 3.0 Hz, 1H), 5.29 (d, J = 
6.5 Hz, 4H), 4.54 (ddd, J = 10.2, 6.6, 3.7 Hz, 1H), 3.77 – 3.59 (m, 8H), 2.80 (p, J 
= 7.3 Hz, 3H), 2.45 – 2.38 (m, 2H), 1.85 (dd, J = 14.7, 7.1 Hz, 3H), 1.71 (dq, J = 
9.2, 4.5, 3.4 Hz, 3H), 1.60 (q, J = 5.0 Hz, 3H), 1.50 (ddd, J = 11.4, 8.0, 5.0 Hz, 
4H), 1.44 – 1.39 (m, 2H), 0.95 (t, J = 6.5 Hz, 5H). 13C NMR (101 MHz, CDCl3) δ 
150.21, 137.97, 136.49, 127.63, 123.38, 122.25, 122.17, 119.48, 118.79, 111.23, 
100.07, 77.48, 77.41, 77.27, 77.16, 77.10, 76.84, 76.78, 66.39, 60.55, 53.00, 
26.37, 22.69, 21.21, 14.30. 
Compound 16b – isolated primary alcohol 
Compound 16 (4.8 g, 15.1 mmol) was dissolved in 20 mL 
anhydrous THF and the solution was cooled to -78oC. To this 
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solution, 1M DIBAL in THF (40 mL, 60.5 mmol) was added dropwise. The 
reaction was monitored by TLC and went to completion after 2 hours. The 
reaction was quenched at -78oC using a 50 mL of ETOAc and 10 mL of MeOH. 
This solution stirred for 1 hour and was allowed to reach room temperature. 60 
mL of a pH 7 solution of citric acid was added to the quenched reaction mixture 
which was subsequently purified using column chromatography. Compound 16b 
was isolated in 78% yield (3.4 g) in addition to starting material, compound 15 
(1.0 g). 1H NMR (400 MHz, Chloroform-d) δ 8.17 – 8.06 (m, 1H), 7.51 (dd, J = 
7.9, 3.7 Hz, 1H), 7.35 (s, 1H), 7.33 – 7.27 (m, 1H), 7.22 – 7.18 (m, 1H), 2.72 (td, 
J = 7.5, 3.5 Hz, 2H), 1.84 – 1.74 (m, 3H), 1.66 (d, J = 3.8 Hz, 10H), 1.30 – 1.21 
(m, 1H). 13C NMR (101 MHz, CDCl3) δ 130.85, 124.35, 122.50, 122.40, 121.07, 
119.11, 115.39, 83.46, 77.49, 77.47, 77.36, 77.17, 77.15, 76.85, 76.83, 62.95, 
32.71, 31.09, 28.41, 28.39, 25.55, 24.81, 0.15. 
Compound 17 
Compound 16 (3.4 g, 11.7 mmol) was dissolved in 60 mL of DCM 
and imidazole (2.4 g, 35.1 mmol) was stirred in at 0oC. Then, the 
PPh3 (4.6 g, 17.6 mmol) was added in two equal batches separated by 15 
minutes. The I2 (4.5 g, 17.6 mmol) was dissolved in DCM and added last via 
cannula in two batches separated by 15 minutes as well. The reaction was stirred 
at 0oC for one hour then allowed to reach room temperature for an additional 
hour. The reaction mixture was quenched with diluted sodium bicarbonate at 0oC 
and the organic layer was extracted using ether. Compound 17 (4.2 g) was 
purified using column chromotagraphy via a column that was packed utilizing a 
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solution of 5% mixture of triethyl amine and hexane for a 90% yield. 1H NMR 
(400 MHz, C6D6) δ 8.59 – 8.46 (s, 1H), 7.45 – 7.39 (d, J = 7.3 Hz, 2H), 7.34 – 
7.26 (t, J = 7.7 Hz, 1H), 7.24 – 7.20 (d, J = 7.5 Hz, 1H), 2.69 – 2.61 (s, 1H), 2.34 
– 2.31 (s, 2H), 1.48 – 1.42 (p, J = 3.5 Hz, 4H), 1.41 – 1.38 (s, 9H), 0.96 – 0.89 (t, 
J = 7.1 Hz, 1H). 
Compound 18 
Compound 17 (4.2 g, 10.5 mmol) was dissolved in 75 mL of a 
2:1 solution of ether in DMSO at 0oC. To this solution, lithium 
acetylide (2.0 g, 10.5 mmol) was added. The reaction mixture was allowed to stir 
for 1 hour at 0oC then was brought to room temperature. Reaction progress was 
monitored by TLC and allowed to proceed overnight. The reaction mixture was 
quenched at 0oC with EtOAc and sodium bicarbonate and purified using column 
chromatography. 1H NMR (400 MHz, Chloroform-d) δ 7.91 (s, 1H), 7.60 (dd, J = 
7.9, 3.3 Hz, 1H), 7.35 (dd, J = 8.1, 3.6 Hz, 1H), 7.18 (td, J = 8.0, 7.5, 3.0 Hz, 1H), 
7.11 (ddd, J = 10.1, 7.1, 3.3 Hz, 1H), 6.99 (d, J = 3.0 Hz, 1H), 2.78 (td, J = 7.6, 
3.2 Hz, 2H), 2.63 – 2.59 (m, 0H), 2.23 (tdd, J = 6.9, 4.3, 2.5 Hz, 2H), 1.55 (d, J = 
3.9 Hz, 3H). 
Compound 20 
In a 3-neck round bottom flask, commercially available 2-
mercaptopyridine (2.0 g, 17.2 mmol) was dissolved in 50 mL of concentrated 
sulfuric acid at 0oC. Over the course of an hour, NaClO (112 mL) was added via 
an addition funnel. After all of the NaClO had been added, the reaction was 
allowed to stir for 30 minutes at 0oC. The reaction mixture was then diluted with 
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30 mL of water and 30 mL of DCM and quenched with water. The aqueous layer 
was extracted with DCM and dried with Na2SO4 producing compound 20.  
Lead Indole Cyclization Catalytic Conditions 
Compound 21 
The most promising cyclized product of compound 18 utilized a 
combined AgOTf/In(OTf)3 catalyst system. Compound 18 (20 mg, 
0.10 mmol) was dissolved in 5 mL of DCE at room temperature and a 1:1 mixture 
of AgOTf (13 mg, 0.05 mmol) and In(OTf)3 (28 mg, 0.05 mmol) was added with 
the ligand bi-2-napthol (5.7 mg, 0.02 mmol). The reaction mixture was stirred for 
1 hour at room temperature without the reaction proceeding. The reaction was 
then heated to 50oC and allowed to stir over night. The resulting reaction mixture 
produced the desired compound 21 in 20% yield. 1H NMR (400 MHz, 
Chloroform-d) δ 7.79 (s, 1H), 7.47 (td, J = 4.7, 4.0, 2.6 Hz, 1H), 7.08 (ddt, J = 6.9, 
4.3, 2.4 Hz, 2H), 6.95 (d, J = 2.8 Hz, 1H), 5.33 – 5.28 (m, 2H), 3.87 (d, J = 2.6 
Hz, 1H), 3.08 (td, J = 7.2, 3.1 Hz, 1H), 2.83 (ddt, J = 24.3, 7.5, 3.8 Hz, 2H), 2.25 
(d, J = 3.3 Hz, 2H), 2.10 – 1.96 (m, 0H).13C NMR (101 MHz, CDCl3) δ 150.02, 
140.89, 136.25, 129.71, 128.83, 126.64, 126.34, 120.56, 118.99, 117.68, 112.74, 
110.21, 77.32, 77.21, 77.01, 76.69, 53.42, 35.34, 34.32, 33.79, 32.10, 31.59, 
29.97, 29.71, 28.62, 28.46, 24.38, 22.66, 20.86, 19.23, 14.13, 0.00. 
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Compound 16 – Boc protected 
 
47 
 
Confidential Data   
 
 
Compound 16a – sulfone protected indole 
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Compound 16b – isolated primary alcohol 
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